Related Experiment Videos
Vancomycin: pharmacokinetics and administration regimens in neonates
Matthijs de Hoog1, Johan W Mouton, John N van den Anker
1Department of Pediatrics, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands. m.dehoog@erasmusmc.nl
Clinical Pharmacokinetics
|May 14, 2004
Summary
Vancomycin is crucial for treating neonatal infections, particularly coagulase-negative staphylococcal sepsis. Dosing strategies are evolving, focusing on trough concentrations and considering factors like renal function and specific medical conditions for optimal neonatal care.
Area of Science:
- Neonatal pharmacology
- Infectious diseases
- Antibiotic stewardship
Background:
- Late-onset neonatal sepsis impacts outcomes, with coagulase-negative staphylococci increasingly prevalent.
- Vancomycin remains a critical antibiotic in neonatal intensive care units (NICUs).
Purpose of the Study:
- To review the use of vancomycin in neonates over the past three decades.
- To discuss pharmacokinetic properties, dosing, and monitoring of vancomycin in this population.
Main Methods:
- Pharmacokinetic modeling (one- or two-compartment) to describe vancomycin behavior.
- Analysis of factors influencing vancomycin distribution and clearance in neonates.
- Review of microbiological and clinical efficacy data, and toxicity profiles.
Main Results:
- Vancomycin pharmacokinetics in neonates depend on postconceptional age and renal function.
- Conditions like patent ductus arteriosus, indomethacin, or ECMO alter vancomycin's volume of distribution and clearance.
- Nephrotoxicity and ototoxicity are rare; peak serum concentration monitoring is often unnecessary, with a trend towards trough level monitoring.
Conclusions:
- Current guidelines suggest age-independent dosing for neonates without renal failure.
- Renal failure necessitates dose adjustment based on serum creatinine.
- Close monitoring is essential for high-risk neonates, including those with renal issues or on ECMO/indomethacin.